May 29, 2014
Source: Press release
SOTIO, a biotechnology company belonging to the PPF Group, announced that it will present four abstracts highlighting clinical progress and research results on DCVAC/PCa and DCVAC/OvCa treatments and head and neck squamous cell carcinoma at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
SOTIO is developing new medical therapies, focusing on the treatment of cancer and autoimmunity diseases. The company’s current focus is predominantly on an Active Cellular Immunotherapy (ACI) for prostate cancer patients, called DCVAC/PCa, and for patients with ovarian cancer, called DCVAC/OvCa. In addition, research and clinical development is investigating potential uses in patients with lung cancer and head and neck cell carcinoma.
SOTIO will present the following studies evaluating its dendritic cell-based vaccines DCVAC/PCa, DCVAC/OvCa and head and neck cancer experimental data at the 2014 ASCO Annual Meeting:
- Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/PCa (General Poster Session: S Hall A2, Sunday, June 1, 8:00 AM - 11:45 AM Poster Board #162)
- Cancer immunotherapy of patients with biochemical relapse of prostate cancer using dendritic cell-based vaccine DCVAC/PCa (General Poster Session: S Hall A2, Sunday, June 1, 8:00 AM - 11:45 AM Poster Board #166)
- Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer: This poster describes SOTIO’s Phase II program in three distinct stages of ovarian cancer. (General Poster Session: S Hall A2, Sunday, June 1, 8:00 AM - 11:45 AM Poster Board #189B)
- Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-positive versus HPV-negative head and neck squamous cell carcinoma (Clinical Science Symposium: Immunobiology and Immunotherapy; Location: S100bc, Sunday, June 1, 11:30 AM – 1:00 PM CT)
Radek Špíšek, Chief Scientific Officer of SOTIO said: “ASCO's acceptance of our abstracts provides an opportunity to share the preliminary results of SOTIO’s research and clinical development with the world’s leading oncologists, key opinion-formers in immunotherapy and the expert media. Having three posters and one presentation at the world’s most prestigious conference on cancer treatments is an excellent result for a company in SOTIO’s early stage of development.”
SOTIO will also have an exhibition booth at ASCO for those seeking further information (Booth number 22146).
With over 30,000 attendees, the ASCO Annual Meeting is one of the largest and most prestigious educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO's Annual Meeting represent the extent of progress made each year in the fight against cancer.
About SOTIO clinical development:
SOTIO’s current focus is predominantly on a novel Active Cellular Immunotherapy (ACI) for prostate cancer, called DCVAC/PCa. Five “Phase II” clinical trials are currently being carried out for this product. SOTIO commenced the “Phase III VIABLE” global clinical trial in Spring 2014, in order to verify the drug’s safety and efficacy. The company intends to undertake this clinical trial in 19 European countries, as well as in the US, with the goal of enrolling around 1,170 patients. In 2013, SOTIO also launched three “Phase II” clinical trials for a new ACI labelled DCVAC/OvCa for patients with ovarian cancer. These clinical trials are taking place in the Czech Republic, Germany and Poland.